VVN539 / VivaVision - LARVOL DELTA

Double-Masked, Vehicle-Controlled, Randomized, Phase II Study of the Ocular Hypotensive Activity and Safety of VVN539 Ophthalmic Solution. (PubMed, Ophthalmol Sci) - "Additional studies will be required for a more complete evaluation of the utility of VVN539 ophthalmic solution. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • P2 data • Cardiovascular • Glaucoma • Hematological Disorders • Ophthalmology

Phase 2 Study of the Ocular Hypotensive Activity and Safety of VVN539 Ophthalmic Solution (AAO 2023) - "Conclusions VVN539 showed ocular hypotensive activity similar to other agents in this class. Further evaluation will be required to determine its clinical utility."

Clinical • P2 data • Glaucoma • Ophthalmology

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure (clinicaltrials.gov) - P2 | N=63 | Completed | Sponsor: VivaVision Biotech, Inc | Recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Dec 2022 | Trial primary completion date: Jul 2023 ➔ Dec 2022

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: VivaVision Biotech, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: VivaVision Biotech, Inc

New P2 trial • Cardiovascular • Glaucoma • Ophthalmology